title: Thyroid cancer: what to do after fine needle aspiration.
abstract: The incidence of differentiated thyroid cancer (including papillary, follicular, and Hurthle cell carcinoma) has nearly tripled in the past 20 years. Diagnosis, treatment, and long-term management are evolving with advances in radiology, surgical techniques, nuclear medicine, genetics, and targeted therapeutics. Here we detail the current recommended course of action for differentiated thyroid cancer and options on the horizon.
authors.affiliation: Division of Endocrinology, Metabolism, and Lipid Research, Washington University, St. Louis, USA. drometo@dom.wustl.edu
authors.forename: David A
authors.initials: DA
authors.lastname: Rometo
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Baranski
mesh_terms: D044963:Biopsy, Fine-Needle; D002291:Carcinoma, Papillary / Q000473:pathology; D017115:Catheter Ablation; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008923:Missouri / Q000453:epidemiology; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D018570:Risk Assessment; D013954:Thyroglobulin / Q000097:blood; D013964:Thyroid Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000601:surgery; D013965:Thyroidectomy; D013972:Thyrotropin / Q000097:blood
chemical_list: D007457:Iodine Radioisotopes; D013972:Thyrotropin; D013954:Thyroglobulin